DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Omni Shoreham Hotel

2018 年 01 月 22 日 7:00 上午 - 2018 年 01 月 24 日 5:00 下午

2500 Calvert Street NW, , Washington, DC 20008 , USA

Pharmacovigilance and Risk Management Strategies Conference

Session 4: Combination Products

Session Chair(s)

Lisa Melanie Harinstein, PharmD

Lisa Melanie Harinstein, PharmD

Team Leader, Division of Pharmacovigilance, FDA, FDA, United States

Combination products are therapeutic and diagnostic products that combine drugs, devices, and or biological products. Because combination products involve multiple components, they are associated with new regulatory, policy, development, and review challenges. In this session, we explore some of these emerging challenges with combination products, such as adverse event reporting and principles of human factor studies during the development of combination products.

Speaker(s)

John  Weiner, JD

Safety Reporting Rule for Combination Products

John Weiner, JD

Associate Director for Policy, Office of Combination Products, OCPP, OC, FDA, United States

Suranjan  De, MBA, MS

Technical Specifications for Safety Reporting of Combination Products

Suranjan De, MBA, MS

Deputy Director, Regulatory Science, OSE, CDER, FDA, United States

Khaudeja  Bano, DrMed, MD, MS

An Industry Perspective on Combination Products (PMSR)

Khaudeja Bano, DrMed, MD, MS

Vice President, Combination Product Quality, Genentech, United States

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。